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A reduced concentration of Aβ1−42 in CSF is one of the established biomarkers of
Alzheimer’s disease. Reduced CSF concentrations of Aβ1−42 have also been shown
in multiple sclerosis, viral encephalitis and bacterial meningitis. As neuroinflammation is
one of the neuropathological hallmarks of Alzheimer’s disease, an infectious origin of
the disease has been proposed. According to this hypothesis, amyloid pathology is a
consequence of a microbial infection and the resulting immune defense. Accordingly,
changes in CSF levels of amyloid-β peptides should be similar in AD and inflammatory
brain diseases. Aβ1−42 and Aβ1−40 levels were measured in cerebrospinal fluid by ELISA
and Western blotting in 34 patients with bacterial meningitis (n = 9), multiple sclerosis
(n = 5) or Alzheimer’s disease (n = 9) and in suitable controls (n = 11). Reduced
concentrations of Aβ1−42 were detected in patients with bacterial meningitis, multiple
sclerosis and Alzheimer’s disease. However, due to a concurrent reduction in Aβ1−40
in multiple sclerosis and meningitis patients, the ratio of Aβ1−42/Aβ1−40 was reduced
only in the CSF of Alzheimer’s disease patients. Urea-SDS-PAGE followed by Western
blotting revealed that all Aβ peptide variants are reduced in bacterial meningitis, whereas
in Alzheimer’s disease, only Aβ1−42 is reduced. These results have two implications. First,
they confirm the discriminatory diagnostic power of the Aβ1−42/Aβ1−40 ratio. Second,
the differential pattern of Aβ peptide reductions suggests that the amyloid pathology in
meningitis and multiple sclerosis differs from that in AD and does not support the notion
of AD as an infection-triggered immunopathology.
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INTRODUCTION
In addition to amyloid plaque deposition, neuroinflammation is
one of the neuropathological hallmarks of Alzheimer’s disease
(AD) (Heneka et al., 2015). Viral, bacterial and even fungal
antigens have been found in association with the pathognomonic
amyloid-beta (Aβ) depositions (Itzhaki, 2014; Little et al., 2014;
Piacentini et al., 2015; Pisa et al., 2015; Zhan et al., 2016).
The secretion of Aβ peptides during inflammation and the
observation of anti-infective properties of Aβ peptides support
the idea that the production of Aβ peptides provides an immune
defense (Spitzer et al., 2010, 2016; Condic et al., 2014; Kumar
et al., 2016). These and other findings have culminated in
the formulation of the infection hypothesis of AD (Miklossy,
2011). According to this hypothesis, amyloid deposition is
the consequence of ongoing neuroinflammation evoked by a
pathogen that evades the immune system.
In the diagnosis of AD, decreased levels of soluble Aβ
peptide 1-42 (Aβ1−42) in the cerebrospinal fluid (CSF) are widely
accepted as a surrogate for brain amyloidosis (McKhann et al.,
2011; Blennow and Zetterberg, 2015; Jack et al., 2016; Lewczuk
et al., 2017). Fitting perfectly into the infection hypothesis,
reduced levels of Aβ42 are also found in patients with brain
infections, such as bacterial meningitis, herpes encephalitis
or human immunodeficiency virus (HIV)-associated dementia
(Sjögren et al., 2001; Krut et al., 2013). Aβ1−42 is generated during
cleavage of amyloid precursor protein (APP). In addition to
Aβ42, several other Aβ peptide variants with different C- and N-
termini are generated during this process (Wiltfang et al., 2002).
It is hypothesized that it is not the overproduction of Aβ42 that
leads to its deposition but rather an imbalance of the different
Aβ peptide variants (Hasegawa et al., 1999; Jan et al., 2008).
Consequently, the concentration of Aβ1−42 in relation to Aβ1−40,
the most abundant Aβ peptide variant, was found to be superior
to Aβ1−42 alone as a biomarker for AD (Lewczuk et al., 2004,
2015a,b; Janelidze et al., 2016; Niemantsverdriet et al., 2017). If
this imbalance between Aβ42 and Aβ40 that is observed in AD
could also be found in inflammatory brain diseases, those data
would further support the infection hypothesis of AD.
Therefore, this study investigates whether the changes in
Aβ1−42 and Aβ1−40 levels in CSF during AD resemble those
observed in multiple sclerosis (MS) and bacterial meningitis




Samples were collected in the memory clinic of the Department
of Psychiatry, Erlangen, the Neurological Department, Erlangen,
and the Neurological Department of Ludwig-Maximilian-
University (LMU), Munich. Patients or their legal representatives
provided their informed consent, and the study protocol was
approved by the ethics committee of the University Hospital
Erlangen-Nuremberg (project no. 3987) and of LMU Munich
(project no. 349-15 and 174-11). Patients included in this
study underwent psychiatric, neurological, medical and routine
laboratory examinations. Additionally, an MRI scan and a CSF
analysis were performed. The CSF of patients with meningitis
was drawn under emergency conditions, so oligoclonal bands
were not routinely determined. The diagnosis of AD was
made according to the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA)
criteria, taking into account the Aβ42/Aβ40 ratio and the total tau
and phospho-tau levels in the CSF (Albert et al., 2011; McKhann
et al., 2011). The Erlangen Score (ES) algorithm (Lewczuk et al.,
2009, 2015a) was also used to classify patients: all AD patients
had an ES ≥ 3, and all controls had an ES ≤ 1. In reference to
the criteria suggested by Jack et al, the patients within the AD
group were classified according to the presence (+) or absence
(–) of Aβ (A), neurofibrillary tangles (T) and neurodegeneration
(N) as A+/T+/N+, whereas those in the control group were A–
/T–/N– (Jack et al., 2016). Amyloid pathology was evaluated by
the Aβ42/Aβ40 ratio, tau pathology was evaluated by phospho-
tau levels, and neurodegeneration was evaluated by total-tau
levels and temporo-parietal atrophy in the MRI scan. Patients
with intermediate signs of AD pathophysiology were excluded.
MS was diagnosed according to the revised McDonald criteria
(Polman et al., 2011), and meningitis was diagnosed according
to the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines (van de Beek et al., 2016). The
control group comprised five patients with tension headache, one
with schizophrenia, two with idiopathic epilepsy and one with a
depressive episode. CSF samples were collected in polypropylene
tubes, centrifuged within 24 h after sampling and stored in
aliquots at−80◦C until further use.
ELISA
Aβ1−40 and Aβ1−42 levels were quantified with certified ELISA
tests (IBL international GmbH, Hamburg, Germany) according
to the manufacturer’s instructions. Samples were thawed
immediately before the analysis and diluted 1:20 in reagent
diluent. Then, 100 µl of each sample, standard, positive control
or blank were added in duplicate to a pre-coated microtiter plate.
After incubation for 2 h, the plate was washed, and horseradish
peroxidase (HRP)-conjugated detection antibody (clone 82E1)





-tetramethylbenzidine (TMB) was added, and
the plate was read. The analyses were performed under careful
quality control, and a measurement was regarded as valid if the
range-to-average coefficient of the duplicate measurements was
below 20%.
SDS-PAGE/Western Blotting
The immunoprecipitation, urea-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting procedures have been described in detail before
(Wiltfang et al., 2002; Oberstein et al., 2015). In short,
immunoprecipitation was carried out with mouse anti-
amyloid antibody 6E10 (Biolegend, formerly Covance, Koblenz,
Germany), reactive to amino acids 1-16 of the Aβ peptide,
covalently bound to magnetic sheep anti-mouse Dynabeads R©
M-280 (10 mg/ml; Dynal, Hamburg, Germany). Samples
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were loaded onto bicine-SDS gels containing 8M urea and
separated for 55min at 25 mA/gel. After semi-dry blotting
onto polyvinylidene fluoride (PVDF)-membranes with a
discontinuous buffer system, immunolabeling was performed
with the anti Aβ1−x antibody 82E1, which only recognized
Aβ peptides starting with amino acid 1 (1:1,000 in phosphate-
buffered saline-Tris (PBS-T); IBL, Hamburg Germany).
ECL R© (enhanced chemiluminescence) prime (GE Healthcare,
Freiburg, Germany) was used to develop the immunoblots,
and chemiluminescence was detected using an Amersham R©
Imager 600 instrument (GE Healthcare, Freiburg, Germany).
The antibodies (6E10 for the immunoprecipitation and 82E1
for the detection) were chosen to achieve the highest possible
sensitivity in this system.
Statistical Analysis
Statistical analysis was carried out with Prism R© 6.0 (GraphPad
Software Inc., La Jolla, CA, USA). Assuming a Gaussian
distribution, parametric ANOVAs for independent samples
followed by Fisher’s post hoc tests were used to compare
measurements among the different groups. To evaluate the
diagnostic accuracy of the Aβ1−42/Aβ1−40 ratio, a receiver
operating characteristic (ROC) curve was generated. Pearson’s
correlation coefficient (r) was calculated to investigate the
associations between different analytes. The results are presented
as the mean with standard deviations and were considered to be
significant at a p-value< 0.05.
RESULTS
Study Population
Samples were collected according to the same standard operating
procedures at the Department of Psychiatry, Erlangen, and the
NeurologyDepartments in Erlangen andMunich. Due to the ages
at which the different pathologies typically occur, the samples
could not be matched for age. However, there was no statistically
significant age difference between the patients with meningitis
and those with AD or between the controls and the patients
with MS. The patients with meningitis had increased peripheral
leucocyte counts, increased levels of C-reactive protein (CRP)
and CSF protein, cells and erythrocytes and a higher CSF/serum
albumin ratio. Patients with MS had slightly increased CSF
leucocyte counts and positive oligoclonal bands in the CSF
(Table 1).
Reduced Aβ1−42 in AD, MS and Meningitis
All measurements were performed in the same laboratory to
avoid inter-center variations. Aβ1−40 and Aβ1−42 levels were
quantified by ELISA. One patient in the meningitis group had
an Aβ1−42 concentration below the lower limit of quantification
and was excluded from further analysis. As expected, a reduced
concentration of Aβ1−42 was found in AD samples. Additionally,
in MS and bacterial meningitis, concentrations of Aβ1−42 were
reduced (Figure 1A). The concentration of Aβ1−40 also tended to
be reduced inMS andmeningitis but not in AD (Figure 1B). As a
consequence, the ratio of Aβ1−42/Aβ1−40 was reduced only in AD
(Figure 1C). No significant correlations between the increased
TABLE 1 | Patient characteristics—Patient characteristics are presented as the
mean (standard deviation).
Con MS Meningitis AD
N (female) 9 (3) 5 (4) 9 (5) 11 (6)
Age [years] 44.1 (19.7) 36.4 (4.6) 64.8 (19.3) 69.9 (11.2)
Blood leukocytes [/µl] 8.6 (4.1) 6.9 (1.6) 16.9 (7.1) 6.4 (1.7)
Serum CRP [mg/l] 6.6 (13.4) 1.8 (1.3) 227.3 (100.6) 2.2 (2.4)
OCB (+/−) 0/9 5/0 1/2 0/11
Total protein (CSF) [mg/l] 583.3 (113.9) 464.0 (166.1) 4500 (3430) 370.4 (109.7)
Albumin ratio 6.0 (2.2) 7.3 (2.8) 85.0 (70.0) 6.4 (2.1)
Leukocytes (CSF) [/µl] 1.4 (1.3) 22.6 (14.9) 9543 (9827) 1.4 (0.9)
Erythrocytes (CSF) [/µl] 5.0 (10.3) 1.5 (1.3) 1295 (2015) 11.2 (22.7)
N, number; CON, control; MS, multiple sclerosis; AD, Alzheimer’s disease; CRP, C-
reactive protein; OCB, oligoclonal IgG bands on isoelectric focusing; CSF, cerebrospinal
fluid.
values of erythrocytes, leukocytes or protein and the reduced
concentrations of CSF Aβ1−40 or Aβ1−42 were found in patients
with meningitis. The established threshold of 0.05 allowed for the
differentiation of AD patient samples from control samples and
samples from MS and meningitis patients with 100% sensitivity
and 91% specificity.
Reduced Total Amyloid in MS and
Meningitis but Not AD
CSF from representative patients with bacterial meningitis,
multiple sclerosis and AD as well as one control was loaded
directly onto SDS gels containing 8M urea (Figure 2A). To
control for artificially low concentrations of Aβ peptides due to
the increased protein concentrations in meningitis, an additional
separation of CSF from two patients with meningitis and two
controls after immunoprecipitation with the 6E10 antibody was
carried out (Figure 2B). The detection was performed with
the anti-amyloid 82E1 antibody, which is specific for Aβ1−x
variants.
Reduced concentrations of all Aβ peptide variants were
observed in the Western blots of CSF from meningitis patients
(Figure 2). The concentration even dropped below the lower
limit of detection.
DISCUSSION
The concentration of Aβ1−42 in CSF is reduced in patients
with AD, MS and bacterial meningitis. However, the ratio of
Aβ1−42/Aβ1−40 is reduced only in AD, while the concentrations
of all Aβ peptide variants are similarly reduced in the CSF of
patients with bacterial meningitis.
This is the first study to show the distinct changes in
Aβ peptide variants in the CSF during AD compared to
inflammatory brain diseases.
Nevertheless, the study has several limitations. The sample
size is relatively small, and an exact matching of age and
sex was not possible. Sample matching is nearly impossible
for age because AD is usually diagnosed above the age
of 60, while patients with MS become symptomatic before
the age of 50. However, the CSF concentrations of Aβ
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FIGURE 1 | Different Aβ peptide profiles in AD, MS and bacterial meningitis Aβ1−42 (A) and Aβ1−40 (B) as well as the ratio (Aβ1−42/Aβ1−40) (C) were quantified by
ELISA in the CSF of healthy controls (Con) and patients with multiple sclerosis (MS), meningitis (Men) and Alzheimer’s disease (AD). The results are presented as the
mean and standard deviation. Differences were calculated with ANOVA followed by the Fisher’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 2 | Reduced concentration of all Aβ peptides in bacterial meningitis (A) Representative SDS-PAGE/Western blots of directly loaded CSF from patients with
bacterial meningitis (Men), multiple sclerosis (MS), Alzheimer’s disease (AD) and controls (CON). (B) Immunoprecipitated samples from two representative patients with
meningitis and two controls are depicted. The identities of the different Aβ peptide variants were defined in previous studies and are indicated on the left-hand side.
Note that the longer peptides migrate below the shorter ones in this SDS-PAGE system containing urea.
peptides have been reported to be relatively stable throughout
life and to be independent of sex in healthy subjects
(Resnick et al., 2015).
To reduce the possible center effects, a balanced composition
of the control and the meningitis groups was achieved. However,
the samples for the MS group were all collected in Munich, while
the samples for the AD group were all collected in Erlangen.
However, the preanalytical handling of the samples was identical
at all sites, and measurement of the Aβ peptides by ELISA
was carried out in a single laboratory, as was recommended to
effectively reduce center effects (Mattsson et al., 2013).
While Aβ1−42 is reduced in all three diseases, the observation
that the Aβ ratio is reduced in AD but not in meningitis or
MS points to a better diagnostic performance of the Aβ ratio.
This improved performance has also been previously shown
for the differential diagnosis of AD vs. non-neurodegenerative
neuropsychiatric diseases, Lewy-body dementia, Parkinson’s
disease dementia or vascular dementia (Lewczuk et al., 2015b;
Janelidze et al., 2016). Several others have therefore suggested
to replace the measurement of Aβ1−42 with the Aβ ratio
for AD diagnosis (Blennow and Zetterberg, 2015). Our study
suggests that the Aβ ratio not only is able to increase
the diagnostic performance in the differential diagnosis of
neurodegenerative diseases but also helps to differentiate AD
from neuroinflammatory diseases.
In the context of the infection hypothesis of AD, the observed
differences among AD, MS and meningitis point to different
pathophysiological processes behind the changes in CSF Aβ1−42
concentrations. While the processing of APP in AD is changed
in a way that leads to an imbalance between the different Aβ
peptide variants and allows the accumulation of Aβ1−42 into
amyloid plaques, it was hypothesized that APP processing is
impeded during CNS infections (Krut et al., 2013). Reduced
concentrations of secreted (s)APPα and sAPPβ duringmeningitis
support this interpretation (Krut et al., 2013). An alternative
explanation is that serum proteins entering the CSF after
breakdown of the blood brain barrier in meningitis might mask
the detection of Aβ peptides. However, others have found no
differences in Aβ peptide concentrations via ELISA after adding
proteins to the CSF (Bjerke et al., 2010), and our data show
no correlation between increased CSF protein concentrations
and reduced concentrations of Aβ peptides. Additionally, we
performed immunoprecipitation to release the Aβ peptides from
their protein bonds. We suggest that the amyloid peptides build
complexes around the invading pathogens and are therefore
no longer measurable in the CSF (Spitzer et al., 2016). By
agglutinatingmicroorganisms and exerting a direct antimicrobial
activity, Aβ peptides have been shown to accumulate around
microorganisms in vitro (Soscia et al., 2010; Torrent et al.,
2012; Kumar et al., 2016; Spitzer et al., 2016). The increased
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expression and distinct processing of APP during immunological
activation in vitro also favors the idea of an immunological
function and an increased consumption of Aβ peptides during
infections and neuroinflammation in MS (Maler et al., 2008;
Sondag and Combs, 2010; Spitzer et al., 2010). Further research is
necessary to analyze the composition and fate of the Aβ peptides
accumulating around the invading pathogens.
Current knowledge of inflammation-induced changes in Aβ
peptide metabolism is mainly based on studies of acute infections
(Spitzer et al., 2010; Kumar et al., 2016). Although MS is not
an infectious disease, we used samples from MS patients to
investigate the Aβ peptide levels in a chronic inflammatory
disease. Mattsson and his colleagues measured the levels of
Aβ38, Aβ40, and Aβ42 in patients with chronic neuroborreliosis
(Mattsson et al., 2010). In both studies investigating two different
entities causing chronic neuroinflammation, the concentrations
of all measured Aβ peptide variants were reduced (Mattsson
et al., 2010). Therefore, it seems that chronic neuroinfection and
neuroinflammation are also associated with reduced levels of all
Aβ peptides.
Taken together, the results of this study point to different
mechanisms resulting in reduced Aβ1−42 levels in the CSF
of patients with AD, bacterial meningitis or MS. The
Aβ1−42/Aβ1−40 ratio may help to distinguish AD from
neuroinflammatory diseases. Further studies are needed to
confirm these findings.
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